Full length articleConcanavalin A-targeted mesoporous silica nanoparticles for infection treatment

Add time:08/18/2019    Source:sciencedirect.com

The ability of bacteria to form biofilms hinders any conventional treatment for chronic infections and has serious socio-economic implications. For this purpose, a nanocarrier capable of overcoming the barrier of the mucopolysaccharide matrix of the biofilm and releasing its loaded-antibiotic within this matrix would be desirable. Herein, we developed a new nanosystem based on levofloxacin (LEVO)-loaded mesoporous silica nanoparticles (MSN) decorated with the lectin concanavalin A (ConA). The presence of ConA promotes the internalization of this nanosystem into the biofilm matrix, which increases the antimicrobial efficacy of the antibiotic hosted within the mesopores. This nanodevice is envisioned as a promising alternative to conventional treatments for infection by improving the antimicrobial efficacy and reducing side effects.

We also recommend Trading Suppliers and Manufacturers of CONCANAVALIN A TYPE III (cas 11028-71-0). Pls Click Website Link as below: cas 11028-71-0 suppliers

Prev:Comparison of lactate and β-hydroxybutyrate in the treatment of concanavalin-A induced hepatitis
Next:Insights on the kinetics of concanavalin A adsorption on platinum and glassy carbon electrodes from electrochemical impedance spectroscopy data)